The most unsettling part of a leadership transition isn’t always failure. It’s discovering that your success no longer secures your future.
At Nyxoah, Olivier Taelman led Genio, a sleep apnea device, through FDA approval and its U.S. launch. U.S. revenue grew 22% quarter over quarter in Q2 2026.
On October 1, Liam Kelly succeeds him.
One detail makes this appointment compelling: in January, Kelly himself had been replaced as Teleflex’s CEO. His board cited a new strategic phase, against a backdrop of revenue below expectations.
Months later, Nyxoah chooses him to lead… its next strategic phase.
Same leader. Replaceable in one company. Sought after in another.
His capabilities didn’t vanish in between.
The problem to solve changed.
Taelman had commercial experience. He had hired the Chief Commercial Officer and initiated the U.S. launch. The succession process, announced in June, explicitly sought a U.S.-based CEO.
The board is redefining what earns its confidence: the experience required, proximity to the market, the ability to scale.
Power is being redistributed, too.
Inside a company, people make themselves valuable through what they know, the relationships they hold, and the problems they help solve.
Change the strategic priority, and you change the value of those assets.
The person who could secure a critical milestone may carry less weight than the person who can win a hospital account. Someone once consulted on every decision may now be informed after the call has been made.
The org chart may remain intact. Influence has already shifted.
For Kelly, the risk would be to mistake that shift for team buy-in. A new priority can be understood, endorsed in a meeting, then slowed by people who see it as a loss of their own standing.
There is no evidence this is happening at Nyxoah. But it is precisely what a leadership change demands we decode.
Outside the company, Kelly’s power will have limits, too.
He cannot command a physician’s trust, a surgeon’s commitment, a payer’s approval, or a patient’s consent.
262 trained surgeons do not mean 262 regular users. 427 patients awaiting prior authorization do not mean 427 completed implants.
Between potential and results lie human decisions.
That is where his leadership will be tested: understanding hesitation, interests, and dependencies. Securing cooperation from people he has no authority over.
The board can appoint the person who makes the decisions.
It cannot hand him the people who will make those decisions succeed.
#HumintAdvisory
Votre commentaire